Ruiz SJL, López-Ruiz M, Barroso-Rodríguez N, Cantú-Brito C, Violante-Villanueva A, Hernández-Hernández M, Molina-Pérez A, Revilla-Beltri J

Language: Spanish
References: 12
Page: 306-313
PDF size: 200.72 Kb.

ABSTRACT

Introduction: Glatiramer acetate is a treatment approved in relapsing remitting multiple sclerosis (RRMS).
Objectve: To evaluate the effect of study glatiramer acetate on CD4 + T lymphocytes levels with Th1 and Th2 phenotype compared with the reference glatiramer acetate in patients with RRMS for 4 months.
Methods: Multicenter, comparative, longitudinal and prospective blinded investigator. Patients were randomized to one of two glatiramer acetate in a 1:1 ratio. Patients were invited to continue treatment for 24 additional months.
Results: A total of 51 patients were included: 28 (55%) were female, mean age of 35 years, 26 to group test glatiramer acetate and 25 to the reference group. There were no significant differences in age, gender and baseline clinical characteristics between groups. Comparing baseline against the end of treatment, it was observed in both groups decreased serum levels of IFN γ (Th1 response) and an increase in levels of IL-10 (Th2 response). Probioglat^® generated a Th2 response (anti-inflammatory) comparable to Copaxone^®. The results over sVCAM levels showed few change after drug treatment of both test and for the reference. Antibodies anti-glatiramer acetate was observed in one patient treated with reference glatiramer acetate. Adverse events associated with the use of both drugs are also comparable in frequency and severity.
Conclusions: The immune response generated by both molecules is similar, suggesting bioequivalence, at least in these parameters, for both compounds.

REFERENCES

1. Porras-Betancourt M, Núñez-Orozco Lilia, Plascencia-Álvarez NI, Quiñones-Aguilar S, Sauri-Suárez S. Esclerosis Múltiple. Rev Mex Neuroci 2007; 8: 57-66.

2. Domínguez MR, Morales EM, Rossiere ENL, Olan TR, Gutiérrez MJL. Esclerosis múltiple: revisión de la literatura médica. Revista de la Facultad de Medicina de la UNAM 2012; 55: 26-35.

3. Miller AE. Glatiramer acetate in the treatment of multiple sclerosis. Neurol Clin 2005; 23: 215-31.

4. Neuhaus O, Kieseier BC, Hartung HP. Pharmacokinetics and pharmacodynamics of the interferon betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J Neurol Sciences 2007; 259: 27-37.

5. Park E, Cho M, Ki Ch. Correct Use of Repeated Measures Analysis of Variance. Korean J Lab Med 2009; 29: 1-9.

6. Cohen J. A Power primer. Psych Bull. Quantitative methods in psychology 1992; 155-9.

7. Heo M, Leon A. Sample sizes required to detect two-way and Three-way interactions involving slope differences in mixed-effects linear models. Journal of Biopharmaceutical Statistics 2010; 20: 787-802.

8. Kurtzke JF. Historical and clinical perspectives of the expanded disability status scale. Neuroepidemiology 2008; 31: 1-9.

9. Fruns M, Renner V, Scherpenise J, Ruedi P. Avances en Esclerosis Múltiple-Tratamiento. Rev Med Clin Condes 2008; 19: 462-5.

10. Boster A, Bartoszek MP, O’Connell C, Pitt D, Racke M. Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 2011; 4: 319-32.

11. Chen M, Gran B, Costello K, Johnson K, Martin R, Dhib-Jalbut S. Glatiramer acetate induces Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Multiple Sclerosis 2001; 7: 209-19.

12. Kim HJ, Ifergan I, Antel JP. Type 2 Monocyte and Microglia differentiation mediated by Glatiramer Acetate Therapy in Patients with Multiple Sclerosis. J Immunol 2004; 172: 7144-53.